N, N-dimethyltryptamine (BMND01) / Biomind - LARVOL DELTA

Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Biomind Labs Inc. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry

Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety (clinicaltrials.gov) - P1/2 | N=40 | Active, not recruiting | Sponsor: Biomind Labs Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Mood Disorders • Psychiatry

Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Biomind Labs Inc.

New P1/2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design. (PubMed, Polymers (Basel)) - "This will enable future studies to assess the possibility of using this formulation to treat certain mental disorders. We have successfully developed a promising thermosensitive and mucoadhesive hydrogel with a gelling temperature of around 32 °C, a viscosity close to 100 mPas and a mucoadhesion of nearly 4.20 N·m."

Journal • CNS Disorders • Mental Retardation • Psychiatry

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial. (PubMed, Eur Neuropsychopharmacol) - "While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. Inhaled DMT might be an efficient, non-invasive, safe route of administration, which might simplify the clinical use of this substance. This is the first clinical trial to test the effects of inhaled DMT (BMND01 candidate)."

Journal • P1 data • CNS Disorders • Mood Disorders • Psychiatry

Clinical Study of DMT in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Biomind Labs Inc. | Recruiting ➔ Completed

Trial completion • BDNF • CRP • IL10 • IL6 • TNFA

Clinical Study of DMT in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Biomind Labs Inc.

New P1 trial • BDNF • CRP • IL10 • IL6 • TNFA

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression (Businesswire) - "Biomind Labs...announced today that it has commenced dose administration of the first subject in a Phase I/IIa clinical trial of the Company’s novel drug candidate BMND01, for treatment-resistant depression with inhaled administration....This first phase of the study includes up to thirty healthy patients and dosing is expected to be completed in approximately four months."

Trial status • CNS Disorders • Depression

Biomind Labs Files International Patent Application on Its DMT Candidates Across 153 Global Jurisdictions (Businesswire) - "Biomind Labs Inc...is pleased to announce that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries....'The patent application enables our proprietary technology on N, N-dimethyltryptamine ('DMT') to be a potential treatment of neurological and psychiatric disorders.'"

Patent • CNS Disorders • Depression

Biomind Labs to Advance a Phase II Clinical Trial on DMT for Treatment-Resistant Depression (Businesswire) - "Biomind Labs Inc...is pleased to announce that its Phase II clinical trial on N, N-dimethyltryptamine ('DMT') for treatment-resistant depression has been approved by the Brazilian Institutional Review Board....The Phase II clinical trial will be conducted by Dr. Draulio Barros de Araujo, will include 40 individuals and will be conducted in Brazil."

New P2 trial • CNS Disorders • Depression